BDBM383753 US10280150, Cmpd No I-36::US10550099, Compound I-156

SMILES COc1nc(N[C@@H](C)c2cc3cc(Cl)ccc3[nH]c2=O)ncc1C#N

InChI Key InChIKey=QAFWVLDKBWIXLX-UHFFFAOYSA-N

Data  20 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 383753   

TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 120nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132G mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 81nMAssay Description:Inhibition of IDH1 R132H mutant (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 130nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132C mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 233nMAssay Description:Inhibition of IDH1 R132C mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 18nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 18nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP], mitochondrial(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 7.66E+4nMAssay Description:Inhibition of IDH2 R140Q mutant (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP], mitochondrial(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 3.38E+4nMAssay Description:Inhibition of IDH2 R172K mutant (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 1.49E+3nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132S mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 60nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132L mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 45nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 3.50E+4nMAssay Description:Inhibition of wild-type IDH1 (unknown origin) by NADPH fluorescence based assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 3.20E+3nMAssay Description:Inhibition of human ERG by patch clamp methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

Curated by ChEMBL
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 130nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132C mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 550nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 550nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 550nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
Go to US Patent